Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings for its first quarter after the closing bell on Thursday, May 7.

Analysts expect the Foster City, California-based company to report quarterly earnings of $1.91 per share, up from $1.81 per share in the year-ago period. The consensus estimate for GILD's quarterly revenue is $6.92 billion (it reported $6.67 billion last year), according to Benzinga Pro.

On April 29, Gilead Sciences announced FDA new drug application acceptance for daily oral HIV treatment BIC/LEN.

Gilead Sciences shares gained 2.1% to close at $136.30 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Citigroup analyst Geoff Meacham maintained a Buy rating and increased the price target from $156 to $165 on April 13, 2026. This analyst has an accuracy rate of 71%.
  • Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and increased the price target from $171 to $175 on April 10, 2026. This analyst has an accuracy rate of 62%.
  • Jefferies analyst Akash Tewari initiated coverage on the stock with a Buy rating and a price target of $180 on March 10, 2026. This analyst has an accuracy rate of 54%.
  • Needham analyst Joseph Stringer maintained a Buy rating with a price target of $170 on Feb. 23, 2026. This analyst has an accuracy rate of 69%.
  • RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $103 to $118 on Feb. 11, 2026. This analyst has an accuracy rate of 52%.

Considering buying GILD stock? Here’s what analysts think:

Photo via Shutterstock